UBS Group Reiterates €147.00 Price Target for Sartorius (SRT3)

Sartorius (FRA:SRT3) has been given a €147.00 ($170.93) price target by equities researchers at UBS Group in a research note issued to investors on Thursday, Borsen Zeitung reports. The brokerage currently has a “neutral” rating on the stock. UBS Group’s price target suggests a potential downside of 4.85% from the company’s previous close.

SRT3 has been the topic of a number of other research reports. Berenberg Bank set a €110.00 ($127.91) price objective on shares of Sartorius and gave the stock a “neutral” rating in a report on Tuesday, January 29th. Deutsche Bank set a €150.00 ($174.42) price objective on shares of Sartorius and gave the stock a “neutral” rating in a report on Thursday, April 11th. Nord/LB set a €90.00 ($104.65) price objective on shares of Sartorius and gave the stock a “sell” rating in a report on Tuesday, February 5th. HSBC set a €116.00 ($134.88) price objective on shares of Sartorius and gave the stock a “neutral” rating in a report on Tuesday, February 5th. Finally, Warburg Research set a €153.50 ($178.49) price objective on shares of Sartorius and gave the stock a “neutral” rating in a report on Wednesday, February 20th. Five equities research analysts have rated the stock with a sell rating and four have assigned a hold rating to the company’s stock. The company presently has a consensus rating of “Sell” and a consensus target price of €122.89 ($142.89).

Shares of Sartorius stock opened at €154.50 ($179.65) on Thursday. Sartorius has a 52-week low of €71.00 ($82.56) and a 52-week high of €124.70 ($145.00).

About Sartorius

Sartorius Aktiengesellschaft supplies pharmaceutical and laboratory equipment worldwide. It operates in two divisions, Bioprocess Solutions, and Lab Products & Services. The company offers products for suspension cell analysis and live-cell analysis inside incubator for oncology, immuno-oncology, antibody discovery, neuroscience, and stem cell research; cell culture media, including antibody and recombinant protein, viral vaccines, and regenerative medicine media, as well as general media and downstream buffers; and multi-parallel, single-use, benchtop, stainless steel, microbial, and cell culture bioreactors, as well as cell culture expansion systems and software applications for bioreactors.

Recommended Story: How Important is Technical Analysis of Stocks

Analyst Recommendations for Sartorius (FRA:SRT3)

Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.